NVCRHIGH SIGNALFINANCIAL10-K

NVCR underwent a major balance sheet restructuring with current liabilities dropping 70.5% and total assets declining 35.2%, while operating cash flow deteriorated significantly and interest expense nearly doubled.

The dramatic reduction in liabilities suggests a major debt restructuring or conversion event, which aligns with the removal of convertible note dilution language from risk factors. However, the company's operational performance is weakening with operating cash flow declining 85.9% and cash reserves dropping 42.9%, indicating potential liquidity pressures despite the balance sheet restructuring.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

NVCR shows signs of a major financial restructuring with current liabilities falling 70.5% from $756.4M to $223.2M and total assets declining 35.2% to $804.3M, suggesting significant debt conversion or settlement activity. Despite reducing net losses by 19.2%, operational cash flow deteriorated sharply by 85.9% to -$49.0M while cash reserves dropped 42.9% to $93.5M, indicating underlying business challenges persist. The 90.5% increase in interest expense to $22.2M, combined with declining cash and worsening operating cash flow, signals potential liquidity concerns despite the apparent debt restructuring.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+90.5%
$11.7M→$22.2M

Interest expense surged 90.5% — significant debt increase or rising rates materially impacting earnings.

Operating Cash Flow
Cash Flow
-85.9%
-$26.4M→-$49.0M

Operating cash flow fell 85.9% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Liabilities
Balance Sheet
-70.5%
$756.4M→$223.2M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-47.3%
$880.6M→$463.9M

Liabilities reduced 47.3% — deleveraging improves balance sheet strength and financial flexibility.

Cash & Equivalents
Balance Sheet
-42.9%
$163.8M→$93.5M

Cash declined 42.9% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-41.6%
$1.1B→$646.7M

Current assets declined 41.6% — monitor working capital adequacy and short-term liquidity.

Capital Expenditure
Cash Flow
-37.8%
$42.9M→$26.6M

Capex reduced 37.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Assets
Balance Sheet
-35.2%
$1.2B→$804.3M

Total assets contracted 35.2% — asset sales, write-downs, or balance sheet optimization underway.

Accounts Receivable
Balance Sheet
+20.5%
$74.2M→$89.4M

Receivables grew 20.5% — monitor days sales outstanding for collection efficiency.

Net Income
P&L
+19.2%
-$168.6M→-$136.2M

Net income grew 19.2% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
lawmakers to agree on a budget or appropriation legislation to fund the federal government s operations (also known as a government shutdown), which could have an adverse effect on regulatory agencies, such as the U.S.
PMA processing) and Centers for Medicare Medicaid Services (e.g.
payment processing), to perform their duties the impact our operations and the financial markets and other businesses reactions to any such failure, or other disruptions outside of our control; our cash needs; and our prospects, financial condition and results of operations.
BUSINESS Overview We are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric fields that exert physical forces to kill cancer cells.
Our key priorities are to drive commercial adoption of Optune Gio , Optune Lua , and Optune Pax , our commercial TTFields therapy devices, obtain regulatory approval to market TTFields therapy devices in new indications, such as brain metastases from non-small cell lung cancer ("NSCLC"), and to advance clinical and product development programs intended to extend overall survival in some of the most aggressive forms of cancer.
Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic NSCLC concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
We also have a CE certificate to market Optune Lua concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen for the treatment of metastatic NSCLC in the EU.
In addition, we received regulatory approval for Optune Lua for the treatment of adult patients with unresectable advanced/recurrent NSCLC concurrent with PD-1/PD-L1 inhibitors following progression on or after a platinum-based regimen in Japan.
We have also have a CE certificate in the EU and approval or local registration to market Optune Lua for the treatment of MPM in certain other countries.
Optune Pax is approved by the FDA under the PMA pathway for the treatment of adult patients with locally advanced pancreatic cancer concurrent with gemcitabine and nab-paclitaxel.
REMOVED
Transactions relating to our convertible notes may dilute the ownership interest of existing shareholders, or may otherwise depress the price of our ordinary shares.
BUSINESS Overview We are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.
Our key priorities are to drive commercial adoption of Optune Gio and Optune Lua , our commercial TTFields therapy devices, and to advance clinical and product development programs intended to extend overall survival in some of the most aggressive forms of cancer.
Our therapy is delivered through a medical device and we continue to advance our Products with the intention to extend survival and maintain quality of life for patients.
Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer ("NSCLC") concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
We have also received CE certification in the EU and approval or local registration to market Optune Lua in certain other countries for the treatment of MPM.
We are actively evaluating opportunities to expand our international footprint.
In June 2024, we presented results from the Phase 3 METIS clinical trial evaluating the use of TTFields therapy and best supportive care for the treatment of adult patients with 1-10 brain metastases from NSCLC following stereotactic radiosurgery ("METIS").
The METIS trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for patients treated with TTFields therapy and supportive care compared to patients treated with supportive care alone.
In December 2024, we announced the top-line results from the Phase 3 PANOVA-3 clinical trial evaluating the use of TTFields therapy together with gemcitabine and nab-paclitaxel for the treatment of adult patients with unresectable, locally advanced pancreatic cancer ("PANOVA-3").
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →